PPD will take Belgian firm's drugs through Phase II
Get the latest news alerts: Follow LTW at Twitter
Local Tech Wire
WILMINGTON, N.C. — PPD Inc. (Nasdaq: PPDI) said Tuesday that it has signed a deal with Belgian drug-maker Janssen Pharmaceutica N.V. to take two developmental compounds through Phase II trials and possibly to market.
The Belgian company, part of Johnson & Johnson, has been working on the drugs to treat, respectively, diarrhea-predominant irritable bowel syndrome (IBS-d) and complicated skin and skin structure and respiratory infections.
Under two agreements, PPD has in-licensed the two compounds and will advance them through Phase II development, PPD said. After that, Janssen can resume development and commercialization and pay PPD up to $330 million in clinical and sales milestones and royalties if the drugs go to market.
Alternatively, PPD can continue developing and commercializing either compound if Janssen does not buy it back. If PPD gets both drugs, it will pay Janssen up to $250 million in clinical and sales milestones and royalties on sales, the company said in an announcement.
Copyright 2012 WRAL Tech Wire. All rights reserved.
Featured
E-mail Preferences
The Skinny
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming
- Entrepreneurship remains at heart of Tech Wire mission
- Flashback: Tech Wire launched 10 years ago today
- Silicon Valley's 'most provocative voice' - Former RTP exec Vivek Wadhwa